Array BioPharma Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
298
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$11.4B
- Investors
-
1
Array BioPharma General Information
Description
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.
Contact Information
Website
www.arraybiopharma.comCorporate Office
- 3200 Walnut Street
- Boulder, CO 80301
- United States
Corporate Office
- 3200 Walnut Street
- Boulder, CO 80301
- United States
Array BioPharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 30-Jul-2019 | $11.4B | Completed | Generating Revenue | ||
| 9. Debt Refinancing | 01-Nov-2017 | Completed | Generating Revenue | |||
| 8. PIPE | 10-Jun-2013 | Completed | Generating Revenue | |||
| 7. PIPE | 02-May-2011 | Completed | Generating Revenue | |||
| 6. Debt - General | 19-May-2009 | Completed | Generating Revenue | |||
| 5. Debt - General | 23-Dec-2008 | Completed | Generating Revenue | |||
| 4. IPO | 17-Nov-2000 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 31-Aug-2000 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 16-Nov-1999 | $8M | $14.6M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 15-Jan-1999 | $6.6M | $6.6M | Completed | Startup |
Array BioPharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 6,800,000 | $1 | $1 | 1x | $1 | 33.62% |
Array BioPharma Comparisons
Industry
Financing
Details
Array BioPharma Competitors (61)
One of Array BioPharma’s 61 competitors is Sinovac Biotech, a Corporation company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sinovac Biotech | Corporation | Beijing, China | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Northwest Biotherapeutics | Corporation | Bethesda, MD | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Oncolytics Biotech | Corporation | Calgary, Canada |
Array BioPharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Array BioPharma Patents
Array BioPharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025202889-A1 | Her2 mutation inhibitors | Pending | 28-Mar-2024 | ||
| US-20260297077-A1 | Erk protein kinase inhibitors | Pending | 17-Apr-2023 | ||
| WO-2024218632-A1 | Erk protein kinase inhibitors | Inactive | 17-Apr-2023 | ||
| JP-2024089651-A | Her2 mutation inhibitors | Pending | 21-Dec-2022 | ||
| AU-2023238523-A1 | Crystalline salt form of a shp2 inhibitor | Active | 23-Mar-2022 | C07D401/14 |
Array BioPharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Array BioPharma Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Boulder Ventures | Venture Capital | Minority | ||
| Falcon Technology Partners | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| Mosaix Ventures | Venture Capital | Minority |
Array BioPharma Investments (2)
Array BioPharma’s most recent deal was a Corporate Asset Purchase with Novartis Pharma (encorafenib (LGX818)). The deal was made on 02-Mar-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Novartis Pharma (encorafenib (LGX818)) | 02-Mar-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Loxo Oncology | 01-Oct-2013 | Early Stage VC | Other Pharmaceuticals and Biotechnology |
Array BioPharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
15.64 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Array BioPharma FAQs
-
When was Array BioPharma founded?
Array BioPharma was founded in 1998.
-
Where is Array BioPharma headquartered?
Array BioPharma is headquartered in Boulder, CO.
-
What is the size of Array BioPharma?
Array BioPharma has 298 total employees.
-
What industry is Array BioPharma in?
Array BioPharma’s primary industry is Drug Discovery.
-
Is Array BioPharma a private or public company?
Array BioPharma is a Private company.
-
What is the current valuation of Array BioPharma?
The current valuation of Array BioPharma is .
-
What is Array BioPharma’s current revenue?
The current revenue for Array BioPharma is .
-
How much funding has Array BioPharma raised over time?
Array BioPharma has raised $482M.
-
Who are Array BioPharma’s investors?
ARCH Venture Partners, Boulder Ventures, Falcon Technology Partners, Frazier Healthcare Partners, and Mosaix Ventures are 5 of 8 investors who have invested in Array BioPharma.
-
Who are Array BioPharma’s competitors?
Sinovac Biotech, Dicerna Pharmaceuticals, Northwest Biotherapeutics, Amgen, and Oncolytics Biotech are some of the 61 competitors of Array BioPharma.
-
When was Array BioPharma acquired?
Array BioPharma was acquired on 30-Jul-2019.
-
Who acquired Array BioPharma?
Array BioPharma was acquired by Pfizer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
